Technologies and decision-support tools for health systems management: a scoping review of features and use cases [0.03%]
用于卫生系统管理的技术和决策支持工具：特征与应用场景的综述式回顾
Ericles Andrei Bellei,Renato Vargas Fernandes,Ana Carolina Bertoletti De Marchi
Ericles Andrei Bellei
Introduction: In the face of growing patient volumes, health requirements, and economic constraints, modern healthcare systems are in dire need of innovative management solutions. Despite a range of tools available to tac...
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 - 2020 [0.03%]
英国2016-2020年成人流感住院患者相关二级医疗资源利用及费用情况
Caroline de Courville,Hélène Bricout,Fabián P Alvarez et al.
Caroline de Courville et al.
Introduction: This study aims to investigate healthcare resource utilization and related costs for influenza virus infections in adults admitted into secondary care in England across four influenza seasons. ...
Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell or solid organ transplantation - a perspective of the German healthcare system [0.03%]
德国医疗卫生体系中关于对中性粒细胞减少、造血干细胞或实体器官移植患者进行全球指南规范的黏菌病诊断费用的观点分析
Sebastian M Wingen-Heimann,Oliver A Cornely,Danila Seidel et al.
Sebastian M Wingen-Heimann et al.
Introduction: Mucormycosis is a rare invasive fungal infection (IFI) which is characterized by prolonged antifungal therapy, high morbidity and mortality rates, as well as increased treatment costs. ...
Correction [0.03%]
改正措施
Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer [0.03%]
新一代ALK抑制剂洛拉替尼与克唑替尼一线治疗阳性非小细胞肺癌的疗效及成本效益分析
YuQi Shang,Hao Guo
YuQi Shang
Objectives: To assess the economic value of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer at medical insurance negotiation prices from the viewpoin...
Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study [0.03%]
利用PHAMOUS研究将精神疾病患者的健康结果量表（HoNOS）和阳性与阴性症状量表（PANSS）映射到EQ-5D-3L中
Anne Kleijburg,Ben Wijnen,Wouter den Hollander et al.
Anne Kleijburg et al.
Objectives: When health outcomes relevant for economic evaluations are unavailable, algorithms can be developed to map utilities using available clinical outcome measures. This study aims to develop two mapping algorithms...
Correction [0.03%]
改正通知书
Content and cost of waste pharmaceuticals collected by pharmacies for disposal [0.03%]
药店收集待处置的废弃药物及其处理成本分析
Mehmet Akif Erişen,Mesut Ardıç
Mehmet Akif Erişen
Background: The research aims to the costs and contents of waste pharmaceuticals collected through pharmacies for disposal. This study adds significant value to the country's economy in terms of cost and number of medicin...
Cost-effectiveness analysis of atezolizumab plus bevacizumab and chemotherapy for the treatment of metastatic, persistent, or recurrent cervical cancer (BEATcc) [0.03%]
阿特珠单抗联合贝伐珠单抗和化疗治疗转移性、持续性或复发性宫颈癌的性价比分析（BEATcc研究）
Yixiao Zhu,Fenghao Shi,Huiting Lin et al.
Yixiao Zhu et al.
Background: The addition of atezolizumab to bevacizumab plus platinum regimen has demonstrated notable improvements in treating metastatic, persistent, or recurrent cervical cancer, but its cost-effectiveness requires fur...
Saco J de Visser,Adam F Cohen
Saco J de Visser